A decrease in the number of orbital decompression surgeries in patients with thyroid eye disease may be attributed to the introduction of teprotumumab treatment, according to a study published in Canadian Journal of Ophthalmology.
“Awareness of TED and newer treatments have had measurable impact on patients seeking treatment,” study co-author Don O. Kikkawa, MD, FACS, of Shiley Eye Institute at UC San Diego Health, told Healio. “In our center, treatment with teprotumumab reduced the overall need to perform orbital decompression in TED patients.”
The retrospective chart